Cascades Reports Third Quarter 2026 Results

Cascades reported Q3 2026 sales of C$1,267 million, up 2% year over year, and adjusted EBITDA of C$162 million, also up 2%; reported EPS rose to C$0.30 from C$0.29, while adjusted EPS fell to C$0.33 from C$0.38. Management cited tariff-related impacts of approximately C$4 million in Packaging alongside higher raw-material and transportation costs, and expects consolidated Q4 results to be slightly lower sequentially. Net debt declined to C$1,863 million and leverage to 3.2x from 3.3x; Cascades declared a C$0.12 quarterly dividend.

Analysis

The sequential rebound is lower quality than consolidated EBITDA suggests: Packaging EBITDA remains below year-ago levels, while most of the consolidated year-over-year improvement came from Corporate/Recovery and Recycling. That may reflect real cost progress, but it is less persuasive evidence of a broad demand or pricing turn; the key test is whether Packaging margins stabilize as input and freight pressure persists. Tissue’s sequential recovery is also vulnerable if price increases cannot continue to offset weaker Away-from-Home volumes.

Cash conversion is the more consequential risk than the headline leverage improvement. Adjusted cash flow generated before specific items was materially weaker year over year, and net debt declined only modestly. Planned asset disposals can support near-term liquidity and debt reduction, but are finite and should not be capitalized as recurring operating cash generation. At 3.2x leverage, another weak cash-conversion quarter could constrain flexibility and keep equity multiple expansion capped even if EBITDA holds up.

Near term, management’s sequentially lower Q4 outlook limits the case for chasing the quarter’s sequential improvement. Over 1–3 months, watch the call for segment-level Q4 expectations and the timing/price certainty of remaining disposals. Over 6–18 months, the thesis turns on sustained cost productivity, packaging recovery, and organic cash flow replacing asset-sale proceeds. Contrarian angle: the stable consolidated margin can obscure deterioration in the larger Packaging contribution; conversely, corporate cost savings and Tissue pricing may prove more durable than a one-quarter snapshot implies.

Key Decisions for Investors

• Do not chase CAS on the sequential EBITDA rebound; maintain a cautious/market-weight stance until Q4 reporting demonstrates stabilization in Packaging EBITDA and cash conversion. The supplied outlook points to sequential pressure, not an imminent earnings inflection.
• For existing CAS exposure, consider a modest relative-value underweight versus a diversified Canadian equities benchmark rather than an outright short: upside could come from further cost actions or disposal proceeds, while weak organic cash generation and 3.2x leverage constrain the risk/reward. Reassess after the Q4 release.
• Track quarterly adjusted cash flow after working-capital movements, net debt, and realized disposal proceeds separately. A further leverage reduction supported by operating cash—not asset sales—or sustained Packaging margin recovery would falsify the cautious thesis; continued disposal dependence or renewed leverage increases would strengthen it.
• On the earnings call, verify the remaining disposal timetable and proceeds, Q4 segment-level margin assumptions, tariff and freight exposure, and whether the cash-flow deterioration is working-capital timing or operating weakness. Avoid treating the disposal objective as recurring free cash flow.